This positive scientific opinion was issued to MSD Ltd for pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC).
The scientific opinion includes:
a public assessment report
a treatment protocol:
for healthcare professionals
on the pharmacovigilance system
Information and details regarding patient access
For new patients wishing to access EAMS medicines in England, trusts must submit an application form to email@example.com to register the patient with NHS England. The form itself can be requested from the same dedicated EAMS email address. Plans are underway to introduce a web based application form as soon as possible. Trusts will be informed when this is available.
For information about access in Wales, contact the Welsh Government Department of Health and Social Services by emailing Andrew Evans, Interim Chief Pharmaceutical Officer at Andrew.Evans@wales.gsi.gov.uk and Karen Eveleigh, Head of Pharmacy and Prescribing policy at Karen.Eveleigh@wales.gsi.gov.uk.